PCN264 Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin in Combination with Daunorubicin and Cytarabine for the Treatment of Acute Myeloid Leukaemia in Portugal

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s302097 ◽

2021 ◽

Vol Volume 13 ◽

pp. 263-277

Author(s):

Maria Mareque ◽

Pau Montesinos ◽

Patricia Font ◽

José María Guinea ◽

Adolfo de la Fuente ◽

...

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment ◽

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s328284 ◽

2021 ◽

Vol Volume 13 ◽

pp. 645-646

Author(s):

Maria Mareque ◽

Pau Montesinos ◽

Patricia Font ◽

José María Guinea ◽

Adolfo de la Fuente ◽

...

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment ◽

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK

PharmacoEconomics - Open ◽

10.1007/s41669-021-00278-3 ◽

2021 ◽

Author(s):

T. Alexander Russell-Smith ◽

James Brockbank ◽

Carla Mamolo ◽

Christopher Knight

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Line Treatment ◽

First Line ◽

The Uk ◽

First Line Treatment ◽

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

Leukemia Research ◽

10.1016/j.leukres.2004.01.009 ◽

2004 ◽

Vol 28 (9) ◽

pp. 987-990 ◽

Cited By ~ 38

Author(s):

Pier Paolo Piccaluga ◽

Giovanni Martinelli ◽

Michela Rondoni ◽

Michele Malagola ◽

Stavroula Gaitani ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Continuous Infusion ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Gemtuzumab ozogamicin in acute myeloid leukaemia

Nature Reviews Clinical Oncology ◽

10.1038/nrclinonc.2012.83 ◽

2012 ◽

Vol 9 (6) ◽

pp. 310-311 ◽

Cited By ~ 6

Author(s):

Farhad Ravandi ◽

Hagop Kantarjian

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

Expert Opinion on Biological Therapy ◽

10.1517/14712598.1.5.893 ◽

2001 ◽

Vol 1 (5) ◽

pp. 893-901 ◽

Cited By ~ 41

Author(s):

Eric L Sievers

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Efficacy And Safety ◽

First Relapse ◽

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-018-0153-4 ◽

2018 ◽

Vol 16 (1) ◽

Cited By ~ 3

Author(s):

Gabriel Tremblay ◽

Mike Dolph ◽

Sachin Patel ◽

Patricia Brandt ◽

Anna Forsythe

Keyword(s):

Acute Myeloid Leukemia ◽

United Kingdom ◽

Cost Effectiveness ◽

Myeloid Leukemia ◽

Standard Of Care ◽

The United Kingdom ◽

Effectiveness Analysis ◽

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Leukemia ◽

10.1038/leu.2012.229 ◽

2012 ◽

Vol 27 (1) ◽

pp. 75-81 ◽

Cited By ~ 109

Author(s):

A K Burnett ◽

◽

R K Hills ◽

A E Hunter ◽

D Milligan ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Older Patients ◽

Low Dose ◽

Remission Rate ◽

Gemtuzumab Ozogamicin ◽

DGI-038 Gemtuzumab Ozogamicin as Salvage Treatment in Children with Acute Myeloid Leukaemia Relapse: A Retrospective Study

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2013-000276.304 ◽

2013 ◽

Vol 20 (Suppl 1) ◽

pp. A109.2-A109

Author(s):

A Giroud ◽

K Morand ◽

G Benoit ◽

G Leverger

Keyword(s):

Retrospective Study ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Salvage Treatment ◽

Leukaemia Relapse ◽

Cost Effectiveness Analysis of Azacitidine in Patients with Acute Myeloid Leukemia With >30% Blasts and who are Not Candidate for Curative-Intend Chemotherapy

Value in Health ◽

10.1016/j.jval.2018.04.213 ◽

2018 ◽

Vol 21 ◽

pp. S33

Author(s):

PJ Villeneuve ◽

D Coyle

Keyword(s):

Acute Myeloid Leukemia ◽

Cost Effectiveness ◽

Myeloid Leukemia ◽

Effectiveness Analysis ◽